Previous 10 | Next 10 |
CAMBRIDGE, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it has entered into a private placement led by an undisclosed leading U.S. public investment fund...
Genocea Biosciences ( GNCA +8.5% ) on 30 July, will announce initial data from Part B of Phase1/2a study from first 5 patients, evaluating the combination of GEN-009, neoantigen vaccine and immune checkpoint inhibitor-based regimens in advanced solid tumors. ...
CAMBRIDGE, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced updates to its clinical programs, the neoantigen vaccine GEN-009 and the neoantigen cell therapy, ...
CAMBRIDGE, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its second quarter 2020 financial results and corporate update conference call and live audio webcas...
Inhibigens (inhibitory antigens) are detrimental an otherwise protective immunotherapy Inhibigens alter the tumor microenvironment and drive tumor hyperprogression Inhibigens abolish both global and tumor antigen-specific T cell activity CAMBRIDGE, Mass., June 2...
CAMBRIDGE, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced the filing of an Investigational New Drug (IND) Application with the U.S. Food and Dru...
Data show immune responses occur rapidly after only two vaccinations and can be sustained for more than one year Part B is exploring the vaccine's ability to reduce tumor size beyond the standard-of-care therapy alone CAMBRIDGE, Mass., May 29, 2020 (GLOBE NEWSWIRE) -- Gen...
Dynavax Technologies (NASDAQ: DVAX ) +41% as COVID-19 vaccine trial could start as soon as July. More news on: Dynavax Technologies Corporation, Arbutus Biopharma Corporation, cbdMD, Inc., Stocks on the move, , Read more ...
Genocea Biosciences (NASDAQ: GNCA ) inks a material transfer agreement (MTA) and exclusive license option with Shionogi & Co., Ltd. ( OTCPK:SGIOY ) to develop a novel herpes simplex virus type 2 (HSV-2) vaccine. More news on: Genocea Biosciences, Inc., Shionogi & Co., Ltd., Healt...
CAMBRIDGE, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced it has entered into a material transfer agreement (MTA) and exclusive license option with Shion...
News, Short Squeeze, Breakout and More Instantly...
Genocea Biosciences Inc. Company Name:
GNCA Stock Symbol:
NASDAQ Market:
Genocea Biosciences Inc Ordinary Shares (GNCA) is expected to report for Q4 2022